By mimicking natural cell membranes, liposomes fuse with intestinal and cellular membranes, allowing glutathione to enter cells directly and bypass digestive breakdown
For beneficiaries, the delay means continued restricted access to these drugs unless they qualify under existing Medicare rules, which primarily apply to diabetes rather than weight loss
Same goes for MOTS-C, which is currently in an ongoing Phase 2a clinical trial evaluating its effects on insulin sensitivity in adults with prediabetes and obesity
That brings the price down from $48 to $43.20 per bottle
Second, they raise costs to the system, forcing patients, employers, government plans, and taxpayers to pay their high prices for far longer than necessary
Neither shape is inherently better they simply serve different priorities